Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7228229 | 0.90 | FFAR1 (0.53) | FFAR1FFAR4ITGB1ITGA4 | |
| SCHEMBL3677264 | 0.83 | FFAR1 (0.66) | FFAR1FFAR4ITGB1ITGA4KEAP1 | |
| SCHEMBL7237789 | 0.81 | FFAR1 (0.55) | FFAR1FFAR4 | |
| SCHEMBL1746706 | 0.81 | FFAR1 (0.80) | FFAR1FFAR4 | |
| SCHEMBL7227968 | 0.80 | FFAR1 (0.52) | FFAR1FFAR4 | |
| SCHEMBL12087533 | 0.79 | FFAR1 (0.75) | FFAR1FFAR4KEAP1 | |
| SCHEMBL27637469 | 0.78 | FFAR1 (0.59) | FFAR1FFAR4 | |
| SCHEMBL5162726 | 0.78 | ITGB1 (0.56) | ITGB1ITGA4 | |
| SCHEMBL7227087 | 0.78 | ITGB1 (0.56) | ITGB1ITGA4 | |
| SCHEMBL30644928 | 0.77 | FFAR1 (0.69) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2000071572-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | FFAR1 74/4885FFAR4 107/4885ITGB1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.